Table 2 2023 survey of patients with chronic urticaria of the COVURT cohort
From: Features of chronic urticaria after COVID-19 mRNA vaccine over time
Survey 2023 (n = 61) | |||
Gender | Antihistamine therapy | ||
Female | 39 (64%) | <3 times a week | 13 (42%) |
Male | 22 (36%) | >3 times a week | 6 (19%) |
Age (median, IDR) (missing data n = 1) | 41.5 (35-50) | 1 pill/day | 8 (26%) |
Vaccine received | 2 pills/day | 1 (3%) | |
Spikevax | 56 (92%) | 3 pills/day | 0 |
Cominraty | 3 (5%) | 4 pills/day | 2 (6%) |
missing data | 2 (3%) | missing data | 1 (3%) |
CU after booster | Omalizumab | ||
yes | 56 (92%) | yes ongoing | 1 (2%) |
no | 4 (7%) | yes stopped | 3 (5%) |
unknown | 1 (2%) | no | 54 (89%) |
CU active by June 2023 | missing data | 3 (5%) | |
yes | 32 (52.5%) | Corticosteroids (anytime) | |
no | 29 (47.5%) | yes | 14 (23%) |
Active CU is | no | 47 (77%) | |
inductible | 7 (22%) | NSAIDs exacerbating CU | |
spontaneous | 13 (42%) | yes | 6 (10%) |
both | 12 (39%) | no | 53 (87%) |
If inducible, triggered by | missing data | 2 (3%) | |
dermographism | 13 (68%) | New booster after CU onset | |
sun | 7 (37%) | yes | 3 (5%) |
water | 2 (11%) | no | 58 (95%) |
cold | 5 (26%) | Did CU get worse after the booster | |
sport | 8 (42%) | yes | 0 |
vibration | 2 (11%) | no | 3/3 (100%) |
UCT score | Which vaccine was recevied? | ||
<12 | 16 (50%) | Cominraty | 3/3 (100%) |
> 12 | 16 (50%) | COVID infection after CU onset | |
Unknown | 0 | yes | 27 (44%) |
Mean number of lesion during the past week | no | 31 (56%) | |
None | 6 (19%) | Did CU get worse after COVID | |
<20 | 22 (69%) | yes | 4/27 (15%) |
20-50 | 4 (13%) | no | 23/27 (85%) |
> 50 | 0 | ||
Prurit severity | |||
None | 1 (3%) | ||
Mild (bearable) | 15 (47%) | ||
Medium | 10 (31%) | ||
Severe (interfere with sleep and/or daily activities) | 6 (19%) | ||
